EAACI Biologicals Guidelines - Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old
Loading...
Files
Accepted Version
Date
2021-12-29
Authors
Agache, Ioana
Akdis, Cezmi
Akdis, Mubeccel
Brockow, Knut
Chivato, Tomas
del Giacco, Stefano
Eiwegger, Thomas
Eyerich, Kilian
Giménez-Arnau, Ana
Gutermuth, Jan
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc.
Published Version
Abstract
Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
Description
Keywords
Chronic spontaneous urticaria , GRADE , Guidelines , Omalizumab
Citation
Agache, I., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O. and Jutel, M. (2021) 'EAACI Biologicals Guidelines - Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old'. Allergy, 77(1), pp. 1-338. doi: 10.1111/all.15030
Link to publisher’s version
Copyright
© 2021, European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. This is the accepted version of the following item: Agache, I., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O. and Jutel, M. (2021) 'EAACI Biologicals Guidelines - Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old'. Allergy, 77(1), pp. 1-338, doi: 10.1111/all.15030, which has been published in final form at: https://doi.org/10.1111/all.15030. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.